modimelanotide

Small moleculeexperimental

Modimelanotide (INN; development code AP-214, ABT-719, and ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued. — Wikipedia

Clinical trial activity

5 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2008 (NCT00628264)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • a 816719.1
  • a-816719.1
  • abt719
  • abt 719
  • abt-719
  • abt-719
  • abt-719
  • abt-719
  • ap214
  • ap214
  • ap 214
  • ap-214
  • ap-214
  • ap-214
  • ap214 peptide
  • modimelanotide
  • zp-1480
  • zp-1480

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01897519Phase 2May 1, 2013AbbVie
NCT01777165Phase 2Feb 1, 2013AbbVie
NCT01256372Phase 2Oct 1, 2010Action Pharma A/S
NCT00903604Phase 2May 1, 2009Action Pharma A/S, University of Copenhagen
NCT00628264Phase 2Mar 1, 2008Action Pharma A/S, University of Florida
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Action Pharma A/SFor profit3312008
AbbVieFor profit2212013
University of CopenhagenAcademic/Hospital1012009
University of FloridaAcademic/Hospital1012008
4 organizations
Page 1 / 1